CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
We received an updated WNV package insert; please note the manufacturer and license number has been ...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...
We have now added a new section called the "Assay History List" to the "At A Gla...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...